NIOX Group PLC
82C
Company Profile
Business description
NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.
Contact
1 Robert Robinson Avenue
The Magdalen Centre
The Oxford Science Park
OxfordOX4 4GA
GBRT: +44 3303309356
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
84
Stocks News & Analysis
stocks
What to expect from the January Fed meeting
Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.
stocks
Fortescue costs outpace increasing volume
Higher diesel prices and foreign exchange hit unit cash costs.
stocks
A top global stock to buy after a big change in its forecast
Undervalued by 24%, this wide-moat stock is a buy now.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,260.00 | 1.50 | 0.02% |
| CAC 40 | 8,131.15 | 11.90 | -0.15% |
| DAX 40 | 24,933.08 | 32.37 | 0.13% |
| Dow JONES (US) | 49,412.40 | 313.69 | 0.64% |
| FTSE 100 | 10,148.85 | 5.41 | 0.05% |
| HKSE | 27,068.97 | 303.45 | 1.13% |
| NASDAQ | 23,601.36 | 100.11 | 0.43% |
| Nikkei 225 | 53,017.71 | 132.46 | 0.25% |
| NZX 50 Index | 13,443.49 | 17.25 | -0.13% |
| S&P 500 | 6,950.23 | 34.62 | 0.50% |
| S&P/ASX 200 | 8,935.20 | 8.50 | 0.10% |
| SSE Composite Index | 4,131.89 | 0.72 | -0.02% |